Therapeutic Asset Ratings
6,371 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Pembrolizumab
Metastatic Castration Resistant Prostate Cancer
Lava Therapeutics
P2
BB
(65)
Pembrolizumab
Skin Carcinoma
Essen Biotech
P2
BB
(65)
Pembrolizumab
Ovarian Endometrioid Adenocarcinoma
Roswell Park Cancer Institute
P2
BB
(65)
Pembrolizumab
T-Cell Non-Hodgkin Lymphoma
Yale University
P2
BB
(65)
Pembrolizumab
Small Cell Carcinoma
Thomas Jefferson University
P2
BB
(65)
Pembrolizumab
Squamous Cell Lung Carcinoma
UNC Lineberger Comprehensive Cancer Center
P2
BB
(65)
TRASTUZUMAB
Gastric Adenocarcinoma
Boehringer Ingelheim
P2
BB
(65)
TRASTUZUMAB
Ovarian Carcinoma
OHSU Knight Cancer Institute
P2
BB
(65)
Blinatumomab
B-Cell Non-Hodgkin Lymphoma
Children's Hospital Medical Center, Cincinnati
P2/3
BB
(65)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)
P2/3
BB
(65)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Lung Cancer
University of Chicago
P2/3
BB
(65)
Cetuximab
Colorectal Cancer Metastatic
Charite University, Berlin, Germany
P4
BB
(64)
DARATUMUMAB
Acquired Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
P4
BB
(64)
DARATUMUMAB
Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
P4
BB
(64)
DARATUMUMAB
MRD
The First Affiliated Hospital of Soochow University
P4
BB
(64)
Denosumab
Breast Cancer
Alliance for Clinical Trials in Oncology
P4
BB
(64)
Humax-Cd20
Multiple Sclerosis
University Hospital, Lille
P4
BB
(64)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Hemophagocytic Syndrome
The First Affiliated Hospital of Soochow University
P4
BB
(64)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Sjogren Syndrome
Peking Union Medical College Hospital
P4
BB
(64)
PANITUMUMAB
Cancer
Amgen
P4
BB
(64)
Atezolizumab
Bile Duct Adenocarcinoma
Georgetown University
P3
BB
(64)
Atezolizumab
Differentiated Thyroid Carcinoma
Exelixis
P3
BB
(64)
Atezolizumab
Urethra Transitional Cell Carcinoma
Alliance for Clinical Trials in Oncology
P3
BB
(64)
Atezolizumab
Metastatic Urethral Urothelial Carcinoma
Alliance for Clinical Trials in Oncology
P3
BB
(64)
Atezolizumab
Colon Carcinoma
Baylor College of Medicine
P3
BB
(64)
Showing 426 to 450 of 6,371 assets
Previous
Page 18 of 255
Next